• Corporate
• Markets
• Info-Tech
• Marketing
• Money & Banking
• Agri-Biz & Commodities
• Industry & Economy
• Logistics
• Government
• Opinion
• Variety
• Columns
• States
• Web Extras
• Index

• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books
• Gallery

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

• Rates
  
  

• Ports

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Subscription

• Business Line

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

NEW DELHI: Drug firm Jubilant Organosys on Tuesday said it has extended its research collaboration pact with the US based multinational Eli Lilly for the next five years.

Jubilant through its Bangalore based subsidiary Jubilant Biosys had entered into a drug discovery research collaboration agreement with Eli Lilly in 2005.

Under the terms of the agreement, Jubilant will receive research funding and also success-based discovery and development milestone payments, the company said in a statement.

“The extension with Lilly is a testimony of collaborative efforts of scientists at Lilly and Jubilant and demonstrates the value of this pioneering effort in networked R&D and its true impact on global pharmaceutical industry,” Mr Sri Mosur, Global Drug Discovery and Development President & CEO, Jubilant said. - PTI

Prev: Hyundai posts 28.46% higher sales in November
Next: Hero Honda November sales up 32%

Copyright copy; 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line